The premier service provider of integrated offerings and comprehensive solutions for the development of organoid and extracellular vesicle technologies. OBBI is dedicated to facilitate and accelerate the bioproduction of organoids and extracellular vesicles by providing our partners with access to expert academic resources taking into account the industrial needs i.e. switch from research-grade to scale-up and GMP-compliant grades.
Unité de Service Inserm 63 (US 63), OBBI is a specialized French center based in Occitanie, dedicated to advancing bioproduction for next-generation biotherapies. We bring together a multidisciplinary team with deep expertise in bioprocesses and bioproducts, committed to addressing the needs of both academic and industrial partners. As part of the National Network of Bioproduction Biotherapy Integrators, OBBI fosters innovation and delivers high-value solutions across the biotherapeutic ecosystem.
We provide fully integrated, end-to-end services to support the development and production of organoids and extracellular vesicles. We help our partners accelerate innovation, optimize workflows, and meet the highest standards of reproducibility and scalability.
At OBBI, we combine state-of-the-art technologies with expert-driven processes to ensure success at every stage. Rigorous Quality Controls are embedded throughout development and production to guarantee robust and reproducible outcomes. We tailor each solution to the specific goals of our partners, providing precision, efficiency, and industry-aligned expertise to drive both scientific breakthroughs and market-driven innovation.
DIRECTOR OF INSERM US63
DR Inserm, IRMB Institut
Director of Inserm US63 and Research Director at IRMB in Montpellier. She leads OBBI’s scientific and operational activities. At IRMB, she heads the “Tissue Engineering & Extracellular Vesicles applied to Rheumatic Diseases” team and oversees the ECELLFrance non‑clinical models platform in Montpellier
DEPUTY DIRECTOR OF INSERM US63
PU UT, RESTORE
Louis Casteilla is a Professor of Animal Physiology at the University of Toulouse, Faculty of Engineering Sciences. He also co-heads a RESTORE research GOT-IT team, where he leads pluri-disciplinary and translational projects in regenerative medicine.
Chief Administrative Officer
Oversees the administrative coordination of OBBI’s activities, ensuring procedural compliance with institutional and regional frameworks.
Chief Business Officer
Leads OBBI’s business development and partnerships, promoting innovation and fostering collaboration across academic, clinical, and industrial sectors.
A set of complementary platforms provides access to advanced technologies and scientific expertise to support research and development in the organoid and extracellular vesicle fields.
The EVe Facility provides state-of-the-art technologies and comprehensive services for EV production, isolation, and characterization.
QC Bioprod provides state-of-the-art technologies and expertise in cell characterization, quality controls, genetic stability analysis, and preclinical studies.
A cutting-edge platform specialized in the scalable bioproduction of pre-vascularized, functional human mesenchymal organoids.
The IRSD Organoids Platform develops digestive organoids from adult tissues. IOP offers models derived from healthy, inflammatory, and tumoral tissues.
OBBI is a Service Unit (US 63) managed by the Inserm and supported by the Innovation Strategy France 2030 and the CeBBOc Key Challenge program
Below is a selection of publications highlighting the excellence of OBBI’s facilities and their contributions to advanced research.